CCRM Australia and Therapeutic Innovation Australia collaborate to develop an information system for regenerative medicine

The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to partner with Therapeutic Innovation Australia (TIA) to jointly develop an information system to curate data on the Australian regenerative medicine sector and to serve as both CCRM Australia’s customer relationship management and project management platforms.

This CCRM Australia-TIA collaboration builds upon TIA’s existing investment into the Australian Translational Research Access (ATRAX) database. ATRAX is a cloud-based relational database of research funding outcomes and also contact and capability information on organisations and facilities associated with Australia’s biomedical industry.  ATRAX is the database behind TIA’s unique Pipeline Navigator web app (https://www.therapeuticpipeline.com/navigator), which provides a dynamic map of Australian translational research capabilities.

The Collaboration will curate information on Australia’s regenerative medicine sector through CCRM Australia’s academic, industry and clinician engagements, to support TIA’s Australian Therapeutic Pipeline initiative by identifying regenerative medicine stakeholders and service providers, in both public and private sectors. The goal is to establish clear translation pathways from research to commercialisation. The collaboration will also assist CCRM Australia by building an appropriate information technology platform to support commercialisation projects and related stakeholder engagements.

CCRM Australia CEO Silvio Tiziani noted, “CCRM Australia is fast becoming the ‘go to’ place for information and advice regarding facilities, services and capabilities in the Australian and international regenerative medicine sector. This information system will be invaluable to our ability to provide this reference service.  Even more importantly, because it brings together information from regenerative medicine academia, industry and related service providers it also allows us to capitalise on previously unidentified synergies and opportunities to advance the Australian regenerative medicine sector.”

The development of this regenerative medicine information system marks the first collaboration between CCRM Australia and TIA, with the intention that both parties further explore opportunities to accelerate the translation and commercialisation of innovative medicines for the benefit of public health.

Dr Stuart Newman, CEO of TIA stated “Australia is replete with excellent translational research facilities in many fields including regenerative medicine. However, there are few maps of this particular landscape and our ATRAX database, which powers the innovative Pipeline Navigator, is intended to provide a dynamic picture of Australia’s research capabilities. TIA is delighted to be able to leverage this data resource to assist CCRM Australia achieve its commercialisation aims.”


For further information, please contact:

Dr Emma Gallaher

emma@thesocialscience.com.au / +61 (0)43 8639 878

Dr Stuart Newman

s.newman@therapeuticinnovation.com.au / +61 (0)40 2345 736

About CCRM Australia

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. This venture has received funding through the MTPConnect Project Fund Program – a dollar-for-dollar matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector. MTPConnect is supported by the Australian Government Industry Growth Centres Initiative – learn more at mtpconnect.org.au.

CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry.

Modelled on the highly successful Centre for Commercialization of Regenerative Medicine (CCRM) based in Canada, a leader in developing and commercializing regenerative medicine, cell and gene technologies, and drawing from that organisation’s expertise and industry and capital venture networks established over a five-year period, CCRM Australia is poised to take a leading role in supporting Australia’s fast developing regenerative medicine sector.

About Therapeutic Innovation Australia

TIA was established in 2008 to facilitate access for researchers to excellent translational research services in the fields of biologics, cell therapies, small molecules, preclinical testing and clinical trials.

Through the National Collaborative Research Infrastructure Strategy, TIA leads the ‘Translating Health Discoveries’ project and invests in soft and hard infrastructure at national facilities to support and enable access to translational research facilities that can accelerate the translation of discoveries from the lab to the clinic.